CDC Issues New Interim Guidance on Use of Medication to Prevent HIV Infection Among Heterosexually Active Adults

CDC’s new Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis [PrEP] for the Prevention of HIV Infection in Heterosexually Active Adults is available in the current (August 10, 2012) volume of the Morbidity and Mortality Weekly Report (MMWR). The new guidance provides clinicians with information and key cautions on the use of PrEP for adults at very high risk of HIV acquisition through heterosexual sex (e.g., those with partners known to have HIV infection). Information in the new guidance supplements that found in CDC’s previously released Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex With Men.

More information is available from CDC:

• Press release announcing publication of the new interim guidance
• Fact sheet on PrEP (PDF)

---

Notice of Correction to the Perinatal Guidelines

The July 31, 2012, edition of the Perinatal Guidelines has been amended to remove incorrect information on zidovudine dosing in infants. The incorrect information was included in a footnote to Table 6, Clinical Scenario Summary Recommendations for Antiretroviral Drug Use by Pregnant HIV-Infected Women and Prevention of Perinatal Transmission of HIV-1 in the United States. The Table 6 footnote now directs readers to Table 9, Recommended Neonatal Dosing for Prevention of Mother-to-Child Transmission of HIV, which provides the correct dosing recommendation.

---

AIDSinfo Fact Sheets Provide Need-to-Know Information on HIV and Its Treatment

Are you looking for information on the ABCs of HIV treatment? Check out our fact sheet series, “HIV and Its Treatment.” The series, which is intended for adults and adolescents infected with HIV, their families, and their friends, provides up-to-date information on FDA-approved antiretroviral medications and recommended HIV treatment regimens, tips on treatment adherence, and the basics on HIV testing and prevention. Fact sheets in the series were all recently reviewed to ensure that information provided is consistent with recommendations in the current HHS Adult and Adolescent Antiretroviral (ARV) Guidelines.

AIDSinfo welcomes feedback on the fact sheets, as well as suggestions for additional educational materials. Please send your comments to ContactUs@aidsinfo.nih.gov.

---